On 5 December 2025, Oncoinvent announced the EGM approval of its fully underwritten rights issue of 260 million new shares in the company, raising gross proceeds of NOK 130 million.
Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases in the peritoneum post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting.
ABG Sundal Collier also advised Oncoinvent earlier this year in its merger with BerGenBio, adding approximately NOK 45 million to the company’s cash runway and securing an uplisting to Euronext Oslo Børs. ABG Sundal Collier acted as joint lead manager and joint bookrunner in the rights issue.

Published: 5 Dec, 2025